Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 21;13:1–12. doi: 10.2147/BTT.S114530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Keyel and Reynolds. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Potential mechanisms of acquired NB resistance to dinutuximab.

Notes: Killing of NB cells by dinutuximab requires the antibody to partner with the effector cells, such as NK cells, neutrophils (PMLs), and Mac to kill via ADCC and/or to fix complement on the tumor cell membrane. Based on the data to date, potential mechanisms of acquired resistance to dinutuximab are illustrated and include neutralization of antibody with HACAs and decreased expression or exposure on the cell surface of GD2.

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; HACAs, human anti-chimeric antibodies; Mac, macrophages; NK, natural killer; NB, neuroblastoma; PMLs, polymorphonuclear leukocytes.